Narwhal Capital Management raised its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 12.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 141,743 shares of the company’s stock after buying an additional 15,510 shares during the period. Merck & Co., Inc. comprises about 1.4% of Narwhal Capital Management’s portfolio, making the stock its 17th biggest position. Narwhal Capital Management’s holdings in Merck & Co., Inc. were worth $16,096,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently made changes to their positions in MRK. Industrial Alliance Investment Management Inc. raised its holdings in Merck & Co., Inc. by 2.6% during the 1st quarter. Industrial Alliance Investment Management Inc. now owns 3,193 shares of the company’s stock worth $421,000 after purchasing an additional 80 shares during the last quarter. IRON Financial LLC lifted its stake in Merck & Co., Inc. by 4.6% in the second quarter. IRON Financial LLC now owns 1,811 shares of the company’s stock valued at $224,000 after buying an additional 80 shares during the period. Argent Capital Management LLC increased its stake in shares of Merck & Co., Inc. by 0.8% in the 2nd quarter. Argent Capital Management LLC now owns 10,521 shares of the company’s stock valued at $1,302,000 after acquiring an additional 81 shares in the last quarter. Forza Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 0.8% during the 2nd quarter. Forza Wealth Management LLC now owns 10,480 shares of the company’s stock valued at $1,297,000 after acquiring an additional 82 shares during the period. Finally, Vista Investment Partners LLC boosted its stake in Merck & Co., Inc. by 2.0% during the second quarter. Vista Investment Partners LLC now owns 4,164 shares of the company’s stock worth $516,000 after acquiring an additional 82 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.
Merck & Co., Inc. Price Performance
MRK opened at $106.66 on Wednesday. The firm has a 50-day moving average price of $114.01 and a 200-day moving average price of $122.04. Merck & Co., Inc. has a twelve month low of $99.80 and a twelve month high of $134.63. The company has a quick ratio of 1.22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $270.15 billion, a price-to-earnings ratio of 118.51, a PEG ratio of 1.55 and a beta of 0.39.
Analyst Upgrades and Downgrades
MRK has been the topic of a number of recent research reports. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Tuesday, July 30th. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $132.00 to $134.00 and gave the company an “equal weight” rating in a research report on Thursday, July 11th. UBS Group lowered their price objective on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Sanford C. Bernstein initiated coverage on Merck & Co., Inc. in a research note on Thursday, October 17th. They set a “market perform” rating and a $115.00 price objective on the stock. Finally, Bank of America reduced their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.62.
Check Out Our Latest Analysis on MRK
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Cisco: Why Analysts Are Targeting 35% Gains by Christmas
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What Are the U.K. Market Holidays? How to Invest and Trade
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.